A good model of neuronal death that reproduces the characteristic tau (t) hyperphosphorylation of Alzheimeŕs disease is the use of okadaic acid (OA). The aim of this study was to determine the contribution of a7 and b2* nicotinic acetylcholine receptor (nAChR) subtypes to neuroprotection against OA in the SH-SY5Y cell line by using the selective a7 and b2* nAChR agonists PNU 282987 and 5-Iodo-A85380, respectively. The results of this study show that both a7 and b2* nAChR can afford neuroprotection against OA-induced neurotoxicity. Protection mediated by a7 nAChRs was independent of Ca 21 and involved the intracellular signaling pathway Janus Kinase-2/Phosphatidylinositol-3-kinase/Akt. When Ca 21 entry was promoted through the a7 nAChR by using the a7-selective positive allosteric modulator PNU 120596, protection was lost. By contrast, protection mediated by b2* nAChRs was Ca 21 dependent and implicated the signaling pathways PI3K/Akt and extracellular regulated kinase 1/2. Both a7 and b2* nAChR activation converged on downregulation of GSK3b and reduction of t phosphorylation in cells undergoing cell death induced by OA. Therefore, targeting nAChR could offer a strategy for reducing neurodegeneration secondary to hyperphosphorylation of protein t.
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Alzheimer disease (AD) is characterized by a progressive loss of memory, often with deterioration of language as well as deficits in visual and motor coordination. At the cellular level, it has been shown that cell death (Cummings, 2004) occurs especially in cholinergic neurons (Whitehouse et al., 1982) and that this neuronal death is related to the loss of memory in AD patients (Haass and Selkoe, 2007) . At the molecular level, AD is characterized by the presence of tangles rich in the intracellular microtubule-associated protein tau (s) (Lee and Trojanowski, 1992) and extracellular deposits of amyloid peptides that form senile plaques (Price et al., 1991) . A link between these two proteins has been demonstrated because beta-amyloid can trigger s phosphorylation and the subsequent degeneration of the affected neurons (Alvarez et al., 2002; Busciglio et al., 1995; Liu et al., 2004) . It has also been shown that beta-amyloid fibrils can induce neurotoxicity and s hyperphosphorylation without plaque formation; it therefore seems that beta-amyloid pathology could precede hyperphosphorylation of s and the formation of neurofibrillary tangles and neurodegeneration (Busciglio et al., 1995) In this study, we have focused on s hyperphosphorylation as a mechanism for neuronal death (Irizarry et al., 1997; Pizzi et al., 1995) . In the brains of AD patients, there is a high percentage of hyperphosphorylated s protein (Avila, 2000) and an accumulation, in certain neurons, of paired helical filaments (PHF) in which hyperphosphorylated s is the major protein present (Grundke-Iqbal et al., 1986 , 1988 . Destabilization of microtubules and the consequent decrease in axonal transport is believed to be responsible for retrograde degeneration of neurons in AD (Alonso et al., 1994 (Alonso et al., , 1997 De Vos et al., 2008) and also for cell death in ''in vitro'' models of s hyperphosphorylation (Cowan et al., 2010; Perez et al., 2002; Tanaka et al., 1998) . Inhibition of phosphatases that act on some abnormally phosphorylated sites characteristic of AD (Gong et al., 1994) may also lead to s protein hyperphosphorylation (Tanaka et al., 1998) . These phosphatases include the Ser/Thr PP1, PP2A, and PP2B (Gong et al., 1994; Wang et al., 1995) , and their activity has been shown to be diminished in brain tissue from AD patients (Gong et al., , 1993 .
Okadaic acid (OA), a seaweed toxin, inhibits phosphatases with the preference PP2A > PP1 > PP2B. A consequence of its action is s hyperphosphorylation ''in vivo'' (Tian et al., 2004) and in vitro (Tanaka et al., 1998; Uberti et al., 1997) . It therefore provides a good model that reproduces s hyperphosphorylation and cell death. In this study, we have used OA in the human neuroblastoma cell line SH-SY5Y to model aspects of cell damage relevant to AD (Arias et al., 2005; Cowan et al., 2010.; Perez et al., 2002; Tanaka et al., 1998) , in order to investigate neuroprotective strategies.
There is a body of evidence for nicotinic acetylcholine receptors (nAChRs) exerting neuroprotective effects against a variety of insults (Dajas-Bailador and Wonnacott, 2004; Picciotto and Zoli, 2008) . With respect to AD, nicotinic agonists have been reported to be effective against Ab-induced toxicity in vivo and in vitro (Arias et al., 2005; Kihara et al., 1998) . Their efficacy in s hyperphosphorylation models is less well documented.
The majority of studies have highlighted the a7 nAChR as the main nAChR subtype responsible for neuroprotective effects mediated by nicotinic agonists (Arias et al., 2005; Bitner et al., 2009; Haydar and Dunlop, 2010) . However, non-a7 nAChR subtypes have also been found to contribute to neuroprotection (Tizabi et al., 2004) , depending on the cell type and toxic stimulus. Because the roles of different nAChR subtypes are not fully understood, we have exploited subtype-selective ligands, namely, the a7 nAChR agonist PNU 282987 (Bodnar et al., 2005) , the b*-selective agonist 5-Iodo-A-85380 (5IA 85380) (Mukhin et al., 2000) , and the a7 nAChR-positive allosteric modulator PNU 120596 
in this study
The results demonstrated nAChR-mediated neuroprotection against OA. Protection mediated by a7 nAChRs was independent of Ca 2þ and involved the intracellular signaling pathway JAK2/PI3K/Akt. Sustained activation of a7 nAChR to promote Ca 2þ entry was achieved with the positive allosteric modulator, but under these conditions, protection was lost. In contrast, protection mediated by b2* nAChRs was Ca 2þ dependent and implicated the signaling pathways PI3K/Akt and extracellular regulated kinase 1/2 (ERK 1/2). Both a7 and b2* nAChR activation converged on the inhibition of GSK-3b and consequently s phosphorylation to afford neuroprotection.
MATERIALS AND METHODS
Materials. PNU 282987, 5IA 85380, PNU 120596, AG-490, LY 294002, and PD 98059 were purchased from Tocris Cookson Inc. (Bristol, UK). OA, a-bungarotoxin (BGT), dihydro-b-erythroidine (DHbE), methyllycaconitine (MLA), mecamylamine, and AR-A01448 were purchased from Sigma-Aldrich (St Louis, MO). a-Conotoxin MII and a-conotoxin AuIB were synthesized as previously described (Luo et al., 1998) . Alpha-conotoxin AuIB selectively blocks a3b4 nAChRs and nicotine-evoked norepinephrine release (Luo et al., 1998) .
Culture of SH-SY5Y cells. SH-SY5Y cells were maintained in a 1:1 mixture of F-12 Nutrient Mixture (Ham12) (Sigma-Aldrich, Madrid, Spain) and Eagle's minimum essential medium (EMEM) supplemented with 15 nonessential amino acids, 1mM sodium pyruvate, 10% heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin, and 100 lg/ml streptomycin (reagents from Invitrogen, Madrid, Spain). Cultures were seeded into flasks containing supplemented medium and maintained at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. For assays, SH-SY5Y cells were subcultured in 48-well plates at a seeding density of 1 3 10 5 cells per well. Cells were treated with the drugs before confluence in F-12/EMEM with 1% FBS. These cells, when undifferentiated, express functional nicotinic receptors (Dajas-Bailador et al., 2002a) . All cells used in this study were used at a low passage number (< 13).
Measurement of lactate dehydrogenase activity. Extracellular and intracellular lactate dehydrogenase (LDH) activity was measured spectrophotometrically using a cytotoxicity cell death kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. Total LDH activity was defined as the sum of intracellular and extracellular LDH activity; released LDH was defined as the percentage of extracellular compared with total LDH activity.
Calcium fluorimetry. Increases in intracellular Ca 2þ in confluent cultures of SH-SY5Y cells grown in 96-well plates were monitored as described by Dajas-Bailador et al. (2002a) . In brief, SH-SY5Y cells were washed twice with Tyrode's salt solution (TSS: in mM 137 NaCl, 2.7 KCl, 1.0 MgCl 2 , 2.5 CaCl 2 , 0.2 NaH 2 PO 4 , 12 NaHCO 3 , and 5.5 glucose; pH 7.4) and incubated with the membrane-permeable Ca 2þ -sensitive dye fluo-3 acetoxymethyl ester (10lM) and 0.02% pluronic F127 for 1 h at room temperature in the dark. Cells were then washed twice with TSS before adding 80 ll buffer, with or without nAChR antagonists or PNU 120596, per well. After 10 min, basal fluorescence (excitation 485 nm and emission 520 nm) was recorded for 4 s using a Fluoroskan Ascent fluorescence plate reader (Labsystems, Helsinki, Finland) . nAChR agonists (20 ll) were added using an automatic dispenser, and changes in fluorescence were monitored for a further 10 s. To normalize fluo-3 AM signals, responses from each well were calibrated by determination of the maximum and minimum fluorescence values by addition of 0.2% Triton-X100 (F max ) followed by 40mM MnCl 2 (F min ). Maximum fluorescence responses were calculated as a percentage of F max À F min .
Immunoblotting. SH-SY5Y cells were washed once with cold PBS and lysed in 100 ll ice-cold lysis buffer (1% Nonidet P-40, 10% glycerol, 137 mmol/l NaCl, 20 mmol/l Tris-HCl, pH 7.5, 1 lg/ml leupeptin, 1 mmol/l phenylmethylsulfonyl fluoride, 20 mmol/l NaF, 1 mmol/l sodium pyrophosphate, and 1 mmol/l Na 3 VO 4 ). Protein (30 lg) from the cell lysates was resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes (Amersham). Membranes were incubated with the following antibodies: anti-ERK 1/2 and anti-phospho-ERK 1/2 at 1:1000 (Santa Cruz Biotechnology Inc., Heidelberg, Germany); anti-JAK2, anti-phospho-Tyr-211-JAK2, anti-phospho-Thr-308-Akt, anti-Akt, anti-phospho-Ser-9-GSK3-b, antiphospho-Tyr-216-GSK3-b, and anti-GSK-3b at 1:1000 (Cell Signaling, Izasa S.A., Barcelona, Spain); and anti-b-actin at 1:100,000 (Sigma). Membranes were also incubated with anti-phospho-Ser-396/404-s and anti-s at 1:1000, which were previously used by Lucas et al. (2001) . Appropriate peroxidase-conjugated secondary antibodies at 1:10,000 were used to detect proteins by enhanced chemiluminescence.
Cytoskeleton staining. SH-SY5Y cells were plated on coverslips: 24-48 h after plating the cells, they were separated into four groups: two were treated with EMEM, one with 10lM PNU 282987, and another one with 100lM 5IA 85380 for 24 h. Then, the control group was maintained in EMEM, and the rest of the groups were treated with OA for 5 h. After exposure of the cells to the different treatments, they were rinsed three times with PBS (9g/l NaC1, 10mM NaH 2 PO 4 , 10mM K 2 HPO 4 ). Then, they were fixed in 2% paraformaldehyde in PBS for 15 min and washed three more times with PBS. Cells were permeabilized by exposure to 0.1% triton in PBS for 1 min. Preparations were washed several times with PBS and then incubated at room temperature with rhodamine-labeled 1:1000 phalloidin (Sigma-Aldrich) in PBS. Coverslips were then thoroughly washed with PBS. In the second rinsing, Hoechst (Invitrogen) 194 DEL BARRIO ET AL.
was added (1 ll/ml) in order to mark nuclei, and after the third rinsing, the coverslips were mounted in glycerol-PBS (1:1; vol/vol). Images were taken with a confocal microscope (TCS SPE; Leica, Wetzlar, Germany).
Statistical analysis. Statistically significant differences between groups were determined by an analysis of variance followed by a Newman-Keuls post hoc analysis. The level of statistical significance was taken at p < 0.05.
RESULTS

Effect of Different Nicotinic Agonists and the a7 Allosteric
Modulator PNU 120596 on OA-Induced Toxicity
Exposure of SH-SY5Y cells to 30nM OA for 16 h increased LDH release from 7-10% (basal conditions) to 36-42% (OA treatment), consistent with the induction of modest levels of cell death (Fig. 1) . To determine if nAChRs are able to protect against OA-induced toxicity, we incubated SH-SY5Y cells with either the a7-or b2*-selective agonist PNU 282987 (Parada et al., 2010) or 5IA 85380, respectively, or with the a7 allosteric modulator PNU 120596. With preincubation increasing concentrations of PNU 282987, for 24 h before the addition of OA (see protocol at the top of Fig. 1 ), we observed a gradual reduction in cell death measured as LDH released into the extracellular medium. PNU 282987 exerted a significant but partial protection against OA-induced toxicity at 10 and 30lM (Fig. 1A ). 5IA 85380 also produced significant protection at 100lM (Fig. 1B) . The a7-positive allosteric modulator PNU 120596 alone showed no protection at any of the concentration assayed (0.3-10lM) (Fig. 1C ).
Intracellular Ca
2þ Increases Mediated by PNU 282987, 5IA 85380, and PNU 120596 Plus PNU 282987 SH-SY5Y cells express a3, a5, a7, b2, and b4 nAChR subunits (Gentry and Lukas, 2002; Peng et al., 1994) . In order to determine the effects of PNU 282987 and 5IA 85380 on intracellular Ca 2þ levels and their selectivity on nAChR subtypes, we measured Ca 2þ signals in SH-SY5Y cells loaded with the dye fluo-3. For these experiments, we employed concentrations of the agonists that showed protection in the previous section in order to gather information about the possible neuroprotective mechanisms of action.
PNU 282987 alone did not induce a significant increase in [Ca 2þ ] c at the neuroprotective concentration of 10lM. However, when the agonist was added to cells preincubated with the allosteric modulator PNU 120596, a significant increase in fluorescence was observed, consistent with increased cytosolic Ca 2þ . These [Ca 2þ ] c increases were mediated FIG. 1. Protective effects mediated by the nicotinic agonists PNU 282987 and 5IA 85380 and the a7 allosteric modulator PNU 120596 against OA-induced toxicity. Cells were pretreated for 24 h with increasing concentrations of the a7 nicotinic agonist PNU 282987, the b2* nicotinic agonist 5IA 85380, or the a7-positive allosteric modulator PNU 120596. Thereafter, SH-SY5Y were incubated for 16 h with 30nM OA, and at the end of the experiment, cell death was evaluated by measuring the release of LDH to the extracellular medium (see top of the figure). PNU 282987 (A) and 5IA 85380 (B) offered protection against OAinduced toxicity; however, the a7 allosteric modulator PNU 120596 did not (C). The data represent means ± SEM of triplicates of at least four different batches of cells. * p < 0.05 and **p < 0.01 with respect to OA alone. NACHR REDUCE OKADAIC ACID NEUROTOXICITY 195 by activation of nAChR because the signal was significantly attenuated by the nonselective nAChR antagonist mecamylamine. In particular, these Ca 2þ signals could be attributed to stimulation of the a7 subtype nAChR because the selective a7 nAChR antagonists aBGT and MLA completely inhibited the increases in fluorescence ( Fig. 2A) .
5IA 85380, at the protective concentration of 100lM, produced a significant intracellular Ca 2þ signal by itself (Fig.  2B) . Selective b2* antagonists such as DHbE and a-conotoxin MII or mecamylamine were able to significantly block Ca 2þ signals induced by 5IA 85380. However, a3b4 (a-conotoxin AuIB) or a7 (BGT) antagonists did not modify the [Ca 2þ ] c responses mediated by 5IA 85380.
Therefore, under these experimental conditions, 5IA 85380 appears to be activating heteromeric b2-containing nAChRs, whereas PNU 282987 is activating a7 nAChRs.
Ca
2þ Dependence in the Protective Effects of 5IA 85380 and PNU 282987
To determine the influence of Ca 2þ entry mediated by a7 and b2* nAChRs in the neuroprotective effects afforded by PNU 282987 and 5IA 85380, we performed experiments in the absence or presence of extracellular Ca 2þ . Because prolonged lack of extracellular Ca 2þ can be a toxic stimulus per se, we first performed a time course to determine the minimum time of agonist preincubation required to achieve the maximal protective effect (see protocol on top of Fig. 3 ).
As Figure 3 illustrates, PNU 282987 reduced LDH release in cells injured with OA in a time-dependent manner; cell death was significantly reduced following only 5 min incubation with the agonist, 24 h before exposing the cells to 16 h to OA (Fig.  3A) . In the case of 5IA 85380, protection was significant following 1 h preincubation (Fig. 3B ). For comparability, we selected a 4-h preincubation period for both agonists because this length of exposure produced a level of protection similar to that seen following 24 h preincubation. The presence or absence of extracellular Ca 2þ was maintained only during the 4-h exposure to the nicotinic agonist; thereafter, the medium was replaced with fresh EMEM containing Ca 2þ for 20 h, and OA was then added for 16 h. The results show that protection mediated by 5IA 85380 was dependent on extracellular Ca 2þ (Fig. 3D) , whereas that induced by PNU 282987 was not (Fig. 3C) . Moreover, when cells were pre-and coincubated with the a7 allosteric modulator PNU 120596 in the presence of Ca 2þ , the neuroprotective effect of PNU 282987 was lost (Fig. 3C) . Finally, in the absence of extracellular Ca 2þ , PNU 120596 did not reverse the neuroprotection mediated by PNU 282987 (Fig. 3C) . These results suggest that Ca 2þ entry via b2* nAChR activation is required to afford a neuroprotective effect. However, in the case of the a7 nAChR, PNU 282987 exerted a Ca 2þ -independent neuroprotective effect. Furthermore, as shown by the experiments with the a7 agonist in the presence of the a7 nAChR allosteric modulator that promotes Ca 2þ entry through the a7 nAChR subtype ( Fig. 2A) , protection was lost in a Ca 2þ -dependent way (Fig. 3C ).
JAK2 Is Involved in Protection Mediated by a7 but Not by b2* nAChRs JAK2 is a protein that can be physically associated with a7 nAChRs and activated when nicotine binds to this receptor subtype (Shaw et al., 2002) . To determine if a7 and/or b2* nAChR subtype stimulation could activate this kinase under our experimental conditions, SH-SY5Y cells were incubated with 10lM PNU 282987, 10lM PNU 282987, plus 10lM PNU 120596 or 100lM 5IA 85380 for different times (5, 15, and 30 min and 1 or 24 h) and JAK2 phosphorylation was then analyzed by Western blotting. Cells treated with 10lM PNU 282987 showed maximally phosphorylated JAK2 after 15 min incubation; thereafter, phospho-JAK2 decreased to basal levels (Fig. 4A) . In contrast, 5IA 85380 failed to promote the activation of JAK2 at any of the times tested (Fig. 4B) . Also, no alteration in phospho-JAK2 levels was observed when the a7 agonist was incubated in the presence of the a7 allosteric modulator (Fig. 4C) .
JAK2 has been previously shown to be involved in neuroprotection induced by nicotine via a7 nAChR stimulation in neurons injured with Ab 1-42 (Shaw et al., 2002) . For this reason and because the a7-selective agonist increased JAK2 phosphorylation, we evaluated if the protective effect of PNU 282987 against OA would be lost in the presence of a JAK2 inhibitor, AG-490. To corroborate that JAK2 activation was linked with its action on the a7 and not with the b2* nAChRs, we also included 5IA 85380 in these experiments. As shown in Figure 4D , the protective effect of PNU 282987 was completely prevented by pre-(15 min before) and coincubation with AG-490, but this compound did not affect protection afforded by 5IA 85380. Therefore, these results indicate that JAK2 is linked to a7 nAChR-mediated survival. Moreover, the presence of the a7 allosteric modulator prevented PNU 282987-induced JAK phosphorylation (Fig. 4C) , and this result correlates with the loss of protection under the same drug treatment conditions (see Fig. 1C ).
Implication of PI3K/Akt in the Neuroprotective Effect
Mediated by a7 and b2* nAChR Stimulation
Multiple nicotinic agonists cause activation of PI3K/Akt (Kihara et al., 2001) . PI3K/Akt is known to be one of the targets of JAK2 (Shaw et al., 2002) . To investigate if exposure to a7 and b2* nAChR agonists led to Akt activation, we measured Akt phosphorylation by Western blot analysis. Incubation with PNU 282987 or 5IA 85380 produced a statistically significant activation of Akt at 5 and 15 min for both agonists (Figs. 5A and 5B). To determine if protection afforded by a7 and b2* nAChR was dependent on the PI3K/ Akt pathway, cells were pre-(15 min before) and coincubated with a PI3K inhibitor, LY 294002 (3lM). Protection elicited by PNU 282987 and 5IA 85380 against OA toxicity was prevented by the inhibitor LY 294002 (Fig. 5C ). Taken together, these results indicate that protection obtained with both nicotinic agonists is dependent on activation of PI3K/Akt.
FIG. 3. Time and Ca
2þ dependence of cytoprotection mediated by PNU 282987 and 5IA 85380. As shown in the upper panel, cells were incubated with PNU 282987 (10lM) (A) or 5IA 85380 (100lM) (B) during 5 min, 1 h, 4 h, or 24 h, and then the agonist was removed, and fresh EMEM was added until to complete 24 h; after this period, EMEM was replaced by OA (30nM) for 16 h. At the end of the experiment, cell death was evaluated by LDH. Figures (C) and (D) show the mean of LDH values when agonists were preincubated for 4 h in the presence or absence of extracellular Ca 2þ using the same protocol described above. PNU 120596 (10lM ''PNU 12'') was preincubated for 15 min and coincubated during the application of PNU 282987 (C). Data represent the mean of LDH values normalized with respect to OA alone ± SEM of triplicates of at least six different cultures. *p < 0.05, **p < 0.01, and ***p < 0.001 with respect to OA; # p < 0.05 and The mitogen-activated protein kinase (MAPK) intracellular pathway has also been implicated in neuroprotection processes mediated by nAChR activation (Egea et al., 2007) . To assess if PNU 282987 and/or 5IA 85380 were able to activate ERK 1/2, we measured the phosphorylation of these kinases by Western blot. As shown in Figure 6A , 10lM PNU 282987 by itself did not produce ERK 1/2 phosphorylation at any of the time intervals studied. However, 5IA 85380 significantly increased the level of P-ERK 1/2 after 15 min (Fig. 6B) . To corroborate the involvement of MAPK activation in the neuroprotective effect mediated by 5IA 85380 and not by PNU 282987, we employed an MEK inhibitor, PD 98059. As shown in Figure 6C , the presence of PD 98059 completely inhibited the protection induced by 5IA 85380 but had no effect on that of PNU 282987. From these results, it can be concluded that MEK participates in the neuroprotective effect mediated by b2* but not by a7 nAChR stimulation.
Involvement of GSK-3b in Neuroprotection Induced by a7
and b2* nAChR GSK-3b is a substrate of Akt. Akt phosphorylates GSK-3b at position Ser-9, and this phosphorylation inactivates GSK-3b (Stambolic and Woodgett, 1994) . On the other hand, phosphorylation at Tyr-216 has the opposite effect and activates GSK-3b; however, the kinases responsible for this phosphorylation are not well characterized (Cole et al., 2004; Hughes et al. 1993; Wang et al. 1994) . We therefore measured nAChR agonist-induced GSK-3b phosphorylation by Western blot. As shown in Figure 7 , both PNU 282987 and 5IA 85380 were able to increase Ser-9 phosphorylation after 15 and 5 min incubation, respectively (Figs. 7A and 7B ). Subsequently, this phosphorylation decreased over time, and after 24 h, it was not statistically significantly different from OA control. P-Tyr 216-GSK-3b and total GSK-3b levels were not altered at any of the incubation times (data not shown).
To determinate if GSK-3b inhibition could be involved in the protection mediated by PNU 282987 and 5IA 85380, we conducted a neuroprotection experiment in the presence or absence of a GSK-3b inhibitor, AR-A014418. Figure 7C shows how AR-A014418 alone produced protection against OA and such protection was not statistically different from that obtained with the nicotinic agonists alone. Because the combination of nAChR agonists plus AR-A014418 did not afford a greater neuroprotective effect, we deduce that both agonists were acting through a common mechanism, which involves a transient inactivation of GSK-3b.
To further investigate how nicotinic agonists and the GSK3b inhibitor, preincubated for 24 h before adding OA, induced neuroprotection, we evaluated the activation and the expression of GSK-3b at the end of the experiment, i.e., after OA treatment. Western blot analysis of GSK-3b was carried out after OA exposure for 16 h alone or in the presence of the neuroprotective compounds. As shown in Figure 8A , the expression of total GSK-3b increased after OA treatment, and nicotinic agonists prevented this increased expression to almost basal levels (Fig. 8A) ; a similar effect was obtained with the GSK-3b antagonist AR-A014418. Interestingly, OA produced a significant increase of total P-Tyr 216 that was also significantly reduced by the nicotinic agonists and AR-A014418 (Fig. 8B ).
a7 and b2* Nicotinic Agonists Reduced s Hyperphosphorylation As previously mentioned, OA is an inhibitor of phosphatases that augments s hyperphosphorylation. In addition, one of the kinases involved in s phosphorylation is GSK-3b, whose target in the s substrate is Ser-396/404 (Cho and Johnson, 2004) . The question of how GSK-3b activity affected the phosphorylation on s Ser-396/404 residue was raised. After OA treatment for 16 h in the presence or absence of PNU 282987, 5IA 85380, and AR-A014418, we measured Ser-396/404 s phosphorylation by Western blot. As shown in Figure 9 , PNU 282987, 5IA 85380, and AR-A014418 significantly reduced s phosphorylation induced by OA on its Ser-396/404 residue.
Effect of a7 and b2* Nicotinic Agonists on the Cytoskeleton Alterations Caused by OA OA, besides causing hyperphosphorylation of s, induces changes in the cytoskeleton that are identified with strong retraction and rounding in cell morphology (Cabado et al., 2004; Vale and Botana, 2008; Yoon et al., 2008) . Therefore, we also analyzed how treatment of the cells with nicotinic agonists could modify the changes in the cytoskeleton induced by OA treatment.
As shown in Figure 10 , control cells exposed only to EMEM (Fig. 10A) showed a fibrous cytoarchitecture with a well extended and branched morphology. OA-treated cells showed a retracted morphology with almost no neurites (Fig. 10B) . When cells were preincubated for 24 h with PNU 282987 (10lM) (Fig. 10C ) or 5IA 85380 (100lM) (Fig. 10D ) before adding OA, we observed a partial recovery of the fibrous and branched cytoarchitecture as observed in intact cells. This partial recovery of the cytoarchitecture correlates with the partial neuroprotective effects observed when measured as LDH release (Figs. 1A and 1B) . 
DISCUSSION
Central to this study is the observation that both a7 and b2* nAChR can transduce signals through different mechanisms to provide protection of cells that undergo hyperphosphorylation of s. Ultimately, these distinct signaling pathways converge on the regulation of GSK-3b and reduction of s phosphorylation.
To analyze how Ca 2þ could be involved in the protective effects of PNU 282987 and 5IA 85380, we first measured cytosolic Ca 2þ levels in fluo-3-loaded SH-SY5Y cells. Interestingly, PNU 282987 at the protective concentration of 10lM did not induce a measurable intracellular Ca 2þ increase, but in the presence of the allosteric modulator PNU 120596, it gave a robust intracellular Ca 2þ rise, which was blocked by the a7 nAChR-selective antagonists BGT and MLA. These results are in agreement with those previously reported in bovine chromaffin cells (del Barrio et al., 2011) or PC12 cells (Dickinson et al., 2007) . Unlike PNU 282987, 5IA 85380 alone, at a protective concentration, was able to increase intracellular Ca 2þ levels; this response was blocked by selective b2* antagonists such as DHbE and a-conotoxin MII but not by a7 (Dickinson et al., 2007) or a3b4-selective antagonists, which corroborates the selectivity of 5IA 85380 for b2* nAChR subtype (Dajas-Bailador et al., 2002a; Mukhin et al., 2000) .
The observation that the a7 agonist exerted its protective effect without apparently inducing intracellular Ca 2þ increases is against the belief that Ca 2þ is the second messenger responsible for kinases' intracellular activation involved in neuroprotection mediated by a7 nAChR (Dajas-Bailador et al., 2002b; DonnellyRoberts et al., 1996; Ferchmin et al., 2003) . However, examination of the protective efficacy of PNU 282987 in a medium without Ca 2þ corroborated the Ca 2þ independence of the protective effect. In fact, when Ca 2þ was forced to increase via a7 nAChR activation, with the aid of the positive allosteric modulator, protection was lost in a Ca 2þ -dependent way. In contrast, the protective effect of 5IA 85380 was dependent on extracellular Ca 2þ , which corroborates a previous study in which this agonist offered Ca 2þ -dependent neuroprotection against glutamate-induced toxicity (Ueda et al., 2008) . Taken together, these results indicate that a7 nAChR protection is Ca 2þ independent, whereas b2* nAChR protection is Ca 2þ dependent. Regarding the intracellular signaling pathways involved in the neuroprotective mechanism associated with the nAChR activation, there are several intracellular kinases involved in this process (Buckingham et al., 2009 ). In the case of the a7 nAChR, JAK2 kinase is able to bind to this nAChR subtype under nicotinic stimulation to transduce signals to PI3 kinase and Akt (Shaw et al., 2002) , which results in neuroprotection. Our results show that only stimulation of the a7 and not the b2* nAChR can induce JAK2 phosphorylation. Activation of the JAK2/PI3K/Akt route can be independent of Ca 2þ (Chernyavsky et al., 2009) , which agrees with the results of this study. The implication of this kinase in protection mediated by a7 nAChR was confirmed when protection induced by PNU 282987, but not by 5IA 85380, was lost in cells treated with the JAK2 inhibitor AG-490. Furthermore, the loss of protection by the a7 agonist in the presence of the allosteric modulator seems to be related to the loss of phosphorylation of JAK2 under similar conditions, as determined by the Western blot experiments (Fig. 4C) .
Continuing with the intracellular signaling pathways, data from other groups (Buckingham et al., 2009; Quesada et al., 2008) as well as our own (Arias et al., 2005; Canas et al., 2007) have shown that activation of PI3K/Akt is related to cell survival. In line with these observations, we have seen that both PNU 282987 and 5IA 85380 increased Akt phosphorylation. Furthermore, the PI3K inhibitor LY 294002 blocked the protective effects of the a7 and b2* agonist. Therefore, this signaling pathway is shared by both nAChR subtypes. In the case of a7 nAChR, it has been described that one of the targets of JAK2 is precisely PI3K/Akt (Shaw et al., 2002) ; these kinases can be activated in a Ca 2þ -dependent (Soletti et al., 2010) or independent manner (Chernyavsky et al., 2009) .
Based on a previous study that showed that non-a7 nAChRs are able to activate MAPK/ERK in a Ca 2þ -dependent way (Nakayama et al., 2001) , we evaluated if 5IA 85380 could induce ERK 1/2 phosphorylation. In our experimental conditions, ERK 1/2 activation was only induced by 5IA 85380. Participation of MAPK in b2* nAChR-mediated protection was supported with the experiments with the inhibitor PD 98059 (Fig. 6C) . Because both agonists activated Akt, we tried to identify Akt targets that could be related to the mechanism of action of OA, which induces s hyperphosphorylation. One of the kinases that phosphorylates s is GSK-3b (Grimes and Jope, 2001) , and it is known that P-Akt inactivates GSK-3b by phosphorylation of its Ser-9 (Cross et al., 1995; Srivastava and Pandey, 1998) . We observed that a7 and b2* nAChR stimulation increased phosphorylation of Ser-9-GSK-3b after 15 min, but it decreased after 24 h exposure to the agonist. This temporal pattern excludes sustained inactivation of GSK-3b as a prerequisite for the observed neuroprotection. However, protection mediated by both nAChR subtypes does seem to be related to inhibition of GSK-3b because the combination of AR-A014418 (a GSK-3b inhibitor) with the a7 or b2* nAChR agonist did not afford additional protective effects (Fig. 7G) .
After exposing the cells for 16 h to OA, total GSK-3b expression was increased by almost twofold. Increases in the expression of GSK-3b have been reported in glial progenitor cells of AD patients treated with Ab (He and Shen, 2009 ) as well as in postmortem brain of Alzheimer patients (Lau et al., FIG. 7 . GSK-3b phosphorylation and implication in neuroprotection mediated by PNU 282987 and 5IA 85380. Time course of Ser-9 were analyzed by Western blot in protein extracts obtained from cells treated with 10lM PNU 282987 (A) and 100lM 5IA 85380 (B) during different time periods. (C) Shows the effect of the GSK-3b inhibitor 1lM AR-A014418 on the neuroprotection mediated by 10lM PNU 282987 (''PNU 28'') and 100lM 5IA 85380 (''5IA'') against OA-induced toxicity. Each value is a mean of at least four different cultures ± SEM. *p < 0.05 with respect to the basal in (A and B); *p < 0.05, **p < 0.01, and ***p < 0.001 with respect to OA alone (C).
NACHR REDUCE OKADAIC ACID NEUROTOXICITY 201 1999). In fact, there are several transgenic models that overexpress GSK-3b and reproduce many pathophysiological features of AD (Engel et al., 2006) . Taken together, OA seems to increase the expression of GSK-3b as observed in AD patients. Therefore, reduction of total GSK-3b expression induced by nicotinic agonists and the GSK-3b inhibitor could be an interesting therapeutic approach. Recent studies have shown that lithium, a GSK-3b inhibitor, and tobacco extracts are able to reduce messenger RNA and GSK-3b protein levels, respectively (Mendes et al., 2009; Tian et al., 2009) . Moreover, total Tyr-216-GSK-3b phosphorylation (active levels) was also increased by OA alone, and this increase was significantly reduced by nAChR agonists and AR-A014418.
GSK-3b specifically phosphorylates Ser-396/404 of s (PHF-1, paired helicoidal filament-1) both in cell cultures (Lovestone et al., 1994; Tanaka et al., 1998) and in vivo models (Spittaels et al., 2000) . s Hyperphosphorylation by PP2A inhibition induces a disruption of microtubules causing cell death in SH-SY5Y cells treated with OA (Tanaka et al., 1998) . This microtubule destabilization compromises axonal transport and induces neurodegeneration of neurons with tangles, a widely accepted characteristic in brains of AD patients (Alonso et al., 1994 (Alonso et al., , 1997 . We have observed that OA almost doubled s phosphorylation on its Ser-396/404 and that the a7 and b2* nicotinic agonists, together with the GSK-3b inhibitor, reduced Ser-396/404-s-hyperphosphorylation. Furthermore, cytoskeleton alterations caused by OA were partially reverted with nAChR agonist treatment (Fig. 10) .
Apart from reducing s phosphorylation, nicotinic stimulation also confers neuroprotection and anti-inflammatory actions by activation of some of the intracellular pathways here described (Egea et al., 2007; Kawamata and Shimohama, 2011; Marrero and Bencherif, 2009; Parada et al., 2010) , which could also be contributing to the protective effects observed by both a7 and b2 nAChR activation.
In conclusion, both a7 and b2* nAChR activation can mediate protection against OA. a7 nAChR-mediated protection involves a Ca 2þ -independent JAK2/PI3K/Akt/GSK-3b signaling pathway. In contrast, the Ca 2þ -dependent protective mechanism mediated by b2* nAChR relates to MEK/ERK 1/2, PI3K/Akt activation, and GSK-3b inactivation. However, both signaling pathways converge on GSK-3b downregulation and reduction of phosphorylation of s in cells exposed to OA, which represents a good model of neuronal death related to the characteristic s hyperphosphorylation found in AD patients. Protein samples were collected from cells that were preincubated for 24 h with 10lM PNU 282987, 100lM 5IA 85380, or 1lM AR-A014418, and subsequently, this pretreatment was replaced by medium with 30nM OA for 16 h. Histograms represent the densitometric quantification of total GSK-3b (A) and total Tyr-216 (B) phosphorylation, using b-actin for normalization. Each value is a mean of four different cultures ± SEM. **p < 0.01, ***p < 0.001 with respect to basal levels and # p < 0.05, ## p < 0.01, and ### p < 0.001 with respect to OA alone.
FIG. 9.
Effect of nicotinic agonists and AR-A014418 on Ser-396/404 s phosphorylation in cells treated with OA. Protein samples were collected from cells that were preincubated for 24 h with 10lM PNU 282987, 100lM 5IA 85380, or 1lM AR-A014418, and subsequently, medium was replaced by 30nM OA for 16 h. Histograms represent the densitometric quantification of P-Ser-396/404-s using s total for normalization. Each value is a mean of five different cultures ± SEM. ***p < 0.001 with respect to basal levels and # p < 0.05 with respect to OA alone.
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